linezolid (zyvox) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid appears to be unique in that it blocks the initiation of protein production. Most common adverse reactions include diarrhea, vomiting, headache, nausea, and anemia. Linezolid has the potential for interaction with adrenergic and serotonergic agents. And with monoamine oxidase inhibitors because it’s nonselective inhibitor of monoamine oxidase.   NCATS

Chemistry

  • SMILES: CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC=C(N3CCOCC3)C(F)=C2
  • InChIKey: TYZROVQLWOKYKF-ZDUSSCGKSA-N
  • Mol. Mass: 337.3461
  • ALogP: 1.12
  • ChEMBL Molecule:
    linezolid  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$2.0075 - $246.8685
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

linezolid | linezolide | linezolid sodium chloride | linezolidum | linospan | linox | n-(((s)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide | u 100766 | u-100766 | zyvox | zyvoxid

Organizations (186)

Research & Development (163)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (49)

Approved Indications (6)


 

Bacterial Infections (approved 2000)

Community-Acquired Infections (approved 2000)

Endocarditis

Pneumonia

Pneumonia, Ventilator-Associated (approved 2000)

Skin Diseases, Infectious (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (49)


 

Abscess (Phase 3)

Bacteremia (Phase 4)

Bacterial Infections (Phase 4)

Burns (Phase 1)

Catheter-Related Infections (Phase 4)

Cellulitis (Phase 3)

Community-Acquired Infections (Phase 3)

Critical Illness (Phase 4)

Cross Infection (Phase 3)

Cystic Fibrosis (Phase 2)

Dermatology (Phase 2)

Diabetic Foot (Phase 4)

Endocarditis (Phase 4)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Febrile Neutropenia (Phase 3)

Gram-Positive Bacteria (Phase 1)

Gram-Positive Bacterial Infections (Phase 4)

Healthcare-Associated Pneumonia (Phase 4)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 4)

Infections (Phase 4)

Linezolid (Phase 2)

Lung Diseases (Phase 2/Phase 3)

Lymphoma (Phase 2)

Methicillin-Resistant Staphylococcus aureus (Phase 4)

Neoplasms (Phase 2)

Neurosurgery (Phase 1)

Optic Nerve Diseases (Phase 3)

Osteoarthritis (Phase 4)

Osteomyelitis (Phase 2)

Pneumonia ()

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 4)

Prosthesis-Related Infections (Phase 2)

Skin and Connective Tissue Diseases (Phase 4)

Skin Diseases, Bacterial (Phase 3)

Skin Diseases, Infectious (Phase 3)

Soft Tissue Infections (Phase 4)

Staphylococcal Infections (Phase 3)

Staphylococcal Skin Infections (Phase 2)

Streptococcal Infections (Phase 2)

Surgical Wound Infection (Phase 3)

Syphilis (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Meningeal (Phase 2)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Ventilators, Mechanical (Phase 4)

Wound Infection (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 132
  • # of Trial Organizations: 163

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue